The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.
 
Jessica Thomes Pepin
Consulting or Advisory Role - Seagen
 
Hye Sook Chon
Honoraria - Curio Science; Envision Communications; Guidepoint Global; MJH Healthcare Holdings, LLC
Consulting or Advisory Role - Eisai; Envision Communications
Speakers' Bureau - Clinical Care Options
Travel, Accommodations, Expenses - Agenus
 
Michael J. Sundborg
Employment - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Speakers' Bureau - GlaxoSmithKline
 
Michael A. Gold
Travel, Accommodations, Expenses - ASCCP
 
Byoung-Gie Kim
No Relationships to Disclose
 
Stephanie V. Blank
Stock and Other Ownership Interests - Johnson & Johnson
Research Funding - Aravive (Inst); AstraZeneca (Inst); F. Hoffmann LaRoche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Seagen (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Ji-Hong Liu
No Relationships to Disclose
 
Michael McCollum
Employment - Virginia Oncology Associates
Research Funding - Genentech (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Seagen (Inst)
 
Masahiko Mori
No Relationships to Disclose
 
Kathleen N. Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Great Debates and Updates; Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - AADi; aadi; Alkermes (Inst); AstraZeneca; Blueprint Medicines (Inst); Caris Life Sciences; Clovis Oncology; Duality Biologics (Inst); Eisai; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); Hengrui Pharmaceutical; Immunogen; Iovance Biotherapeutics; Janssen Oncology; Merck; Mereo BioPharma; Mersana (Inst); Myriad Genetics; Novartis; Novartis/Pfizer; Onconova Therapeutics; OncXerna Therapeutics; Regeneron; VBL Therapeutics; Verastem/Pharmacyclics; zentalis
Research Funding - Agenus (Inst); Amgen (Inst); artios (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo/Lilly (Inst); Genentech (Inst); Immunocore (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline
Other Relationship - GOG Partners (Inst)
 
Julian Rivera Diaz
No Relationships to Disclose
 
Charles Andreé Joseph de Padua
No Relationships to Disclose
 
Jerónimo Martínez-García
Consulting or Advisory Role - AstraZeneca Spain; GlaxoSmithKline
Travel, Accommodations, Expenses - MSD Oncology; PharmaMar; Roche
 
Christos Papadimitriou
Honoraria - AstraZeneca; Genesis Therapeutics; MSD Oncology; Novartis
Consulting or Advisory Role - Amgen Astellas BioPharma; Roche
Research Funding - Roche; WinMedica
 
Karin Gri an
Consulting or Advisory Role - GlaxoSmithKline
Speakers' Bureau - Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Genekor; GlaxoSmithKline; MSD; Pfizer
 
Róbert Póka
Consulting or Advisory Role - AstraZeneca; CSL Behring
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Matthew Kowgier
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Emma Oscroft
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Els Van Nieuwenhuysen
Consulting or Advisory Role - AstraZeneca (Inst); Oncoinvent; Regeneron (Inst)
Research Funding - AstraZeneca (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Oncoinvent (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Regeneron (Inst)
 
Shannon Neville Westin
Consulting or Advisory Role - AstraZeneca; BioAscent; Caris Life Sciences; Clovis Oncology; Curio Science; Eisai; EQRX; Genentech; Gerson Lehrman Group; Gilead Sciences; GlaxoSmithKline; Immunocore; Immunogen; Lilly; Medscape; Merck; Mereo BioPharma; Mersana; Mersana; NGM Biopharmaceuticals; Nuvectis Pharma; Nuvectis Pharma; OncLive; pharma&; Roche; Seagen; Targeted Oncology; Vaniam Group; Verastem; Vincerx Pharma; Zentalis; ZielBio
Research Funding - AstraZeneca (Inst); Avenge Bio (Inst); Bayer (Inst); Bio-Path Holdings, Inc (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Jazz Pharmaceuticals (Inst); Mereo BioPharma (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Roche/Genentech (Inst); Zentalis (Inst)